Santen-backed Clearside Biomedical, which had raised some $48m in funding, is offering 7.2 million shares on Nasdaq priced at $7 each.
Clearside Biomedical, a US-based biopharmaceutical company focused on eye diseases that is backed by pharmaceutical firm Santen Pharmaceutical, has priced its initial public offering at $50.4m.
The company is offering 7.2 million shares on Nasdaq at $7 each. The company’s target size was $57.5m, which it would achieve if underwriters choose to exercise their 30-day option of purchasing an additional 1.08 million shares.
Established in 2011, Clearside is working on therapies for conditions of the eye that cause blindness,…
